Psilocybin Research

Single-Dose Psilocybin Promising for Resistant Depression

A single 25-mg dose of a synthetic formulation of psilocybin appears to improve the core symptoms of treatment-resistant depression (TRD), a new analysis of phase 2 trial data suggests.

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Despite the growth of psychedelic research, psychedelic-assisted group psychotherapy (PAGP) has received little attention in comparison to individual psychedelic-assisted psychotherapy models.

Trial of Psilocybin versus Escitalopram for Depression

Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms.

Positive Top-line Results for Novel Psychedelic in Major Depression

An experimental psychedelic tryptamine combined with supportive therapy is associated with improvements in moderate to severe major depressive disorder (MDD), new research suggests.

Psychedelics Research and Psilocybin Therapy

The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses.

Backed by $17 million of funding, researchers build on previous work and expand research on psychedelics for illness and wellness: (1) to develop new treatments for a wider variety of psychiatric and behavioral disorders with the aspiration of treatments tailored to the specific needs of individual patients and (2) to expand research in healthy volunteers with the ultimate aspiration of opening new ways to support human thriving.

Psilocybin for Trauma-Related Disorders

Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD.